METYRAPONE ESTEVE 250 mg, soft capsule 50 capsules
Active ingredients: Metyrapone
Commercialized according to BDPMDispensing in France: Prescription only
Soft capsule50 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- METYRAPONE ESTEVE 250 mg, capsule molle
- Pharmaceutical form
- capsule molle
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 50 capsule(s)
- Marketing authorisation holder
- ESTEVE PHARMACEUTICALS (ESPAGNE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Mar 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68806037CIP73000732CIP133400930007327Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉTYRAPONEcapsule | 250 mg · une capsule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.